Overall verdict
Neutral
5.7/10
1-year performance
+58.47%
Score breakdown
Up 58.5% over 1 year, 70% of the 52-week range.
Strongest: Growth 9.0/10. Weakest: Shareholder return 0.0/10.
26 analysts, target +0.3% vs the price.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling ; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers ; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level ;
and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development ;
GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications ; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes ; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies.
Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
Helmy Eltoukhy
Founded
2011
Employees
2 506
Revenue / employee
391 868 USD
Next earnings
February 18, 2027 (estimated)
Institutional holders
- FMR LLC5.43%
- GEODE CAPITAL MANAGEMENT, LLC1.88%
- Bank of New York Mellon Corp0.72%
- Rest of the register91.97%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
191.05 USD
52-week low
74.55 USD
1-year performance
58.47%
Rising
Year-to-date performance
52.37%
Rising
Drawdown
-18.41%
Marked drawdown
Position in the 52-week range
70% of range
Gross margin 65.2%, the company loses 37.9% of its revenue, ROIC -41.6%, ROE 153.9%.
Net margin
-37.93%
Negative
Sector 4.74%|S&P 13.40%
Gross margin
65.19%
Exceptional
Return on equity (ROE)
153.90%
Exceptional
Sector 10.43%|S&P 17.06%
Return on invested capital (ROIC)
-41.60%
Negative
Free cash flow margin (FCF)
-17.20%
Negative
Margin stability
48.0 pts
Very uneven
Revenue to net income
Growth
9.0/10Revenue up 36.1% over 1 year, 27.9% a year over 5.
Revenue (trailing 12 months)
1.3Md USD
Revenue growth (1y)
36.12%
Hyper-growth
Revenue growth (3y)
118.45%
Strong
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 27.4x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 12.5x|S&P 15.5x
PEG
—
Sector 1.25|S&P 0.91
Market cap
21.1Md USD
Financial strength
6.5/10Cash covers 60.7% of the debt, net debt/EBITDA 0.8x.
Net debt / EBITDA
0.8x
Very solid
Gearing (net debt / equity)
—
Cash
1.0Md USD
Cash / market cap
4.87%
Tight
Cash / total debt
60.71%
Very solid
Interest coverage
-96.6x
Stretched
Net debt
665M USD
Equity
-276M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 155.35 USD
- MM20166.87
- MM50169.19
- MM200132.15
- RSI 1441.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.84%
200-day average slope, 3 months
+18.88%
50-day average slope, 1 month
+0.78%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.52 % per day
Volatility change
+5.86%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -3.35 (14) | -1.45 (21) | 1 366 (24) | -190 (19) | -443 (16) |
| 2027 | -2.05 (13) | -0.30 (20) | 1 847 (25) | 1 (16) | -263 (16) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | GH | 5.7 | 3.6 | 21.1Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | 0.8x | -1.0 % | 58.5 % | ||
| 8 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
